ULTIMATE ACRP CCRC PREP 2027
Q&AS WITH WELL-DEFINED
EXPLANATIONS
Ace your ACRP certification with this premium, fully updated
CCRC Practice Exam Study Guide containing highly realistic
multiple-choice questions. Every question is engineered to match
the latest exam blueprint, featuring correct answers and deep-
dive rationales to reinforce your mastery of ICH GCP E6(R2),
FDA 21 CFR regulations, and clinical site operations. This study
guide is the ultimate resource for students and research
professionals looking to guarantee a passing grade and achieve
an A+ on their certification exam.
Section 1: ICH GCP E6(R2) & Ethical Principles
1. According to ICH GCP E6(R2), who is ultimately
responsible for supervising any individual or
party to whom the investigator delegates study-
related duties at the trial site?
A) The Clinical Research Coordinator (CRC)
B) The Sponsor
C) The Institutional Review Board (IRB)
D) The Principal Investigator (PI)
Rationale: According to ICH GCP 4.2.4, the
investigator should ensure that any
individual or party to whom they delegate
trial-related duties is qualified and should
, maintain responsibilities for supervising
them.
2. What is the primary purpose of the Institutional
Review Board (IRB) / Independent Ethics
Committee (IEC)?
A) To ensure the study completes on budget
B) To safeguard the rights, safety, and well-
being of all human subjects
C) To verify the accuracy of the source data
D) To audit the sponsor's manufacturing facilities
Rationale: ICH GCP 3.1.1 states that an
IRB/IEC should safeguard the rights, safety,
and well-being of all trial subjects, paying
special attention to trials that may include
vulnerable subjects.
3. Which of the following documents must be
obtained and documented prior to a subject's
participation in a clinical trial?
A) Informed Consent Form (ICF)
B) Serious Adverse Event (SAE) form
C) Case Report Form (CRF) Completion Guide
D) Clinical Trial Agreement (CTA)
Rationale: Under ICH GCP 4.8.1, neither the
investigator nor the trial staff should coerce
or unduly influence a subject to participate,
, and freely given informed consent must be
obtained before a subject's participation.
4. If an amendment to an Informed Consent Form
is made during an ongoing trial, who must
approve this amendment before it can be used
to re-consent active participants?
A) The Sponsor's Medical Monitor
B) The Clinical Research Associate (CRA)
C) The Institutional Review Board (IRB) / Ethics
Committee
D) The Food and Drug Administration (FDA)
Rationale: ICH GCP 3.1.2 requires the
IRB/IEC to review and approve all
modifications to the informed consent form
prior to implementation.
5. In an emergency situation where consent from
the subject is not possible and a legally
acceptable representative is not available, what
must the investigator do to enroll the subject?
A) Obtain verbal approval from a witness over
the phone
B) Enroll the subject immediately and document
it after the study completes
C) Ensure the protocol addresses these
measures and has prior documented approval
, from the IRB
D) Skip the consent process entirely without
informing the IRB
Rationale: ICH GCP 4.8.15 states that in
emergency situations, when prior consent of
the subject is not possible, the enrollment
measures must be described in the protocol
and have received prior approval from the
IRB/IEC.
6. According to ICH GCP, how long should
essential documents be retained after the formal
discontinuation or completion of a clinical trial?
A) At least 1 year
B) At least 2 years after the last approval of a
marketing application in an ICH region
C) Exactly 5 years from the database lock
D) Forever, without exception
Rationale: ICH GCP 4.9.5 states essential
documents should be retained until at least 2
years after the last approval of a marketing
application and until there are no pending or
contemplated marketing applications.
7. Who is responsible for providing the investigator
with an up-to-date Investigator's Brochure (IB)?
A) The Sponsor
Q&AS WITH WELL-DEFINED
EXPLANATIONS
Ace your ACRP certification with this premium, fully updated
CCRC Practice Exam Study Guide containing highly realistic
multiple-choice questions. Every question is engineered to match
the latest exam blueprint, featuring correct answers and deep-
dive rationales to reinforce your mastery of ICH GCP E6(R2),
FDA 21 CFR regulations, and clinical site operations. This study
guide is the ultimate resource for students and research
professionals looking to guarantee a passing grade and achieve
an A+ on their certification exam.
Section 1: ICH GCP E6(R2) & Ethical Principles
1. According to ICH GCP E6(R2), who is ultimately
responsible for supervising any individual or
party to whom the investigator delegates study-
related duties at the trial site?
A) The Clinical Research Coordinator (CRC)
B) The Sponsor
C) The Institutional Review Board (IRB)
D) The Principal Investigator (PI)
Rationale: According to ICH GCP 4.2.4, the
investigator should ensure that any
individual or party to whom they delegate
trial-related duties is qualified and should
, maintain responsibilities for supervising
them.
2. What is the primary purpose of the Institutional
Review Board (IRB) / Independent Ethics
Committee (IEC)?
A) To ensure the study completes on budget
B) To safeguard the rights, safety, and well-
being of all human subjects
C) To verify the accuracy of the source data
D) To audit the sponsor's manufacturing facilities
Rationale: ICH GCP 3.1.1 states that an
IRB/IEC should safeguard the rights, safety,
and well-being of all trial subjects, paying
special attention to trials that may include
vulnerable subjects.
3. Which of the following documents must be
obtained and documented prior to a subject's
participation in a clinical trial?
A) Informed Consent Form (ICF)
B) Serious Adverse Event (SAE) form
C) Case Report Form (CRF) Completion Guide
D) Clinical Trial Agreement (CTA)
Rationale: Under ICH GCP 4.8.1, neither the
investigator nor the trial staff should coerce
or unduly influence a subject to participate,
, and freely given informed consent must be
obtained before a subject's participation.
4. If an amendment to an Informed Consent Form
is made during an ongoing trial, who must
approve this amendment before it can be used
to re-consent active participants?
A) The Sponsor's Medical Monitor
B) The Clinical Research Associate (CRA)
C) The Institutional Review Board (IRB) / Ethics
Committee
D) The Food and Drug Administration (FDA)
Rationale: ICH GCP 3.1.2 requires the
IRB/IEC to review and approve all
modifications to the informed consent form
prior to implementation.
5. In an emergency situation where consent from
the subject is not possible and a legally
acceptable representative is not available, what
must the investigator do to enroll the subject?
A) Obtain verbal approval from a witness over
the phone
B) Enroll the subject immediately and document
it after the study completes
C) Ensure the protocol addresses these
measures and has prior documented approval
, from the IRB
D) Skip the consent process entirely without
informing the IRB
Rationale: ICH GCP 4.8.15 states that in
emergency situations, when prior consent of
the subject is not possible, the enrollment
measures must be described in the protocol
and have received prior approval from the
IRB/IEC.
6. According to ICH GCP, how long should
essential documents be retained after the formal
discontinuation or completion of a clinical trial?
A) At least 1 year
B) At least 2 years after the last approval of a
marketing application in an ICH region
C) Exactly 5 years from the database lock
D) Forever, without exception
Rationale: ICH GCP 4.9.5 states essential
documents should be retained until at least 2
years after the last approval of a marketing
application and until there are no pending or
contemplated marketing applications.
7. Who is responsible for providing the investigator
with an up-to-date Investigator's Brochure (IB)?
A) The Sponsor
